Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases, has announced its participation in four major investor conferences in September 2024:
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 4
- 2024 Wells Fargo Healthcare Conference on September 5
- H.C. Wainwright 26th Annual Global Investment Conference on September 11
- 2024 Cantor Fitzgerald Global Healthcare Conference on September 17
The company will participate in fireside chats at each event. Live webcasts of the presentations will be available on Cabaletta Bio's website, with replays accessible for 30 days after each event.
Cabaletta Bio (Nasdaq: CABA), un'azienda biotecnologica in fase clinica focalizzata nello sviluppo di terapie cellulari mirate e curative per le malattie autoimmuni, ha annunciato la sua partecipazione a quattro importanti conferenze per investitori nel settembre 2024:
- 22a Conferenza Sanitaria Globale di Morgan Stanley il 4 settembre
- Conferenza Sanitaria di Wells Fargo 2024 il 5 settembre
- 26a Conferenza Globale sugli Investimenti di H.C. Wainwright l'11 settembre
- Conferenza Sanitaria Globale di Cantor Fitzgerald 2024 il 17 settembre
L'azienda parteciperà a discussioni informali in ciascun evento. Webcast dal vivo delle presentazioni saranno disponibili sul sito web di Cabaletta Bio, con registrazioni accessibili per 30 giorni dopo ciascun evento.
Cabaletta Bio (Nasdaq: CABA), una empresa de biotecnología en etapa clínica centrada en desarrollar terapias celulares dirigidas y curativas para enfermedades autoinmunitarias, ha anunciado su participación en cuatro importantes conferencias de inversores en septiembre de 2024:
- 22ª Conferencia Anual de Salud Global de Morgan Stanley el 4 de septiembre
- Conferencia de Salud de Wells Fargo 2024 el 5 de septiembre
- 26ª Conferencia Anual de Inversión Global de H.C. Wainwright el 11 de septiembre
- Conferencia Global de Salud de Cantor Fitzgerald 2024 el 17 de septiembre
La empresa participará en charlas informales en cada evento. Transmisiones en vivo de las presentaciones estarán disponibles en el sitio web de Cabaletta Bio, con repeticiones accesibles durante 30 días después de cada evento.
카발레타 바이오 (Nasdaq: CABA)는 자가 면역 질환을 위한 치료적 표적 세포 치료제를 개발하는 임상 단계의 생명공학 회사로, 2024년 9월에 네 가지 주요 투자자 회의에 참여한다고 발표했습니다:
- 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스, 9월 4일
- 2024 웰스 파고 헬스케어 컨퍼런스, 9월 5일
- H.C. 웨인라이트 제26회 글로벌 투자 회의, 9월 11일
- 2024 캔토르 피츠제럴드 글로벌 헬스케어 컨퍼런스, 9월 17일
회사는 각 행사에서 대화형 토론에 참여할 예정입니다. 라이브 웹캐스트는 카발레타 바이오의 웹사이트에서 제공되며, 각 행사 후 30일 동안 다시 시청할 수 있습니다.
Cabaletta Bio (Nasdaq: CABA), une entreprise de biotechnologie en phase clinique spécialisée dans le développement de thérapies cellulaires ciblées et curatives pour les maladies auto-immunes, a annoncé sa participation à quatre grandes conférences pour investisseurs en septembre 2024 :
- 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 4 septembre
- Conférence de Santé Wells Fargo 2024 le 5 septembre
- 26e Conférence Annuelle d'Investissement Mondiale de H.C. Wainwright le 11 septembre
- Conférence Mondiale sur la Santé de Cantor Fitzgerald 2024 le 17 septembre
L'entreprise participera à des discussions informelles lors de chaque événement. Des webcasts en direct des présentations seront disponibles sur le site de Cabaletta Bio, avec des rediffusions accessibles pendant 30 jours après chaque événement.
Cabaletta Bio (Nasdaq: CABA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von gezielten, heilenden Zelltherapien für Autoimmunerkrankungen konzentriert, hat seine Teilnahme an vier wichtigen Investorenkonferenzen im September 2024 bekannt gegeben:
- 22. Morgan Stanley Global Healthcare Conference am 4. September
- Wells Fargo Healthcare Conference 2024 am 5. September
- 26. H.C. Wainwright Global Investment Conference am 11. September
- 2024 Cantor Fitzgerald Global Healthcare Conference am 17. September
Das Unternehmen wird an informellen Gesprächsrunden bei jeder Veranstaltung teilnehmen. Live-Webcasts der Präsentationen werden auf der Website von Cabaletta Bio verfügbar sein, mit Aufzeichnungen, die 30 Tage nach jeder Veranstaltung zugänglich sind.
- None.
- None.
PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following investor conferences in September:
- Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Wednesday, September 4, 2024 at 4:50 p.m. ET in New York, NY.
- 2024 Wells Fargo Healthcare Conference: Fireside chat on Thursday, September 5, 2024 at 8:00 a.m. ET in Boston, MA.
- H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Wednesday, September 11, 2024 at 9:00 a.m. ET in New York, NY.
- 2024 Cantor Fitzgerald Global Healthcare Conference: Fireside chat on Tuesday, September 17, 2024 at 11:30 a.m. ET in New York, NY.
A live webcast of each presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.
About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials in myositis, systemic lupus erythematosus, systemic sclerosis, generalized myasthenia gravis and in the RESET-PV™ sub-study within the DesCAARTes™ clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.
Contacts:
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
FAQ
What investor conferences will Cabaletta Bio (CABA) attend in September 2024?
When is Cabaletta Bio's (CABA) presentation at the Morgan Stanley Global Healthcare Conference?
How can investors access Cabaletta Bio's (CABA) conference presentations?
What is the focus of Cabaletta Bio's (CABA) research and development?
